SUBSCRIBE
SUBSCRIBE
News   Drug Development

US FDA Warns Shire Pharmaceuticals (JOBS), Eisai Company, Ltd. (JOBS) on Promotions

November 16, 2009 | 
1 min read
Bookmark and Share

Reuters -- U.S. regulators have warned Shire PLC (SHP.L) and Eisai Co Ltd (4523.T) about drug promotions that minimized the medicines' risks and overstated benefits, letters released on Friday said.
Clinical research Postmarket research Legal Regulatory
MORE ON THIS TOPIC
New Opportunity, Businessman Walks Up Stairs Finds Exit Big Door
FDA
FDA’s cell and gene therapy head steps down after 1 year
June 30, 2026
 · 
2 min read
 · 
Michael Gibney
Accumulated problems, contradictions. Dead end, we need to go back. You cannot continue further. Complete impossibility to continue. Rejection of an idea. Hard sanctions. Fatal error.
Immunology and inflammation
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes
June 30, 2026
 · 
2 min read
 · 
Tristan Manalac
Cancer of the brain as tumor growth diagnosis and symptoms of gliomas meningiomas astrocytomas and oligodendrogliomas as diagnosis of symptoms as a paper sculpture.
Regulatory
FDA hits Praxis with 3-month delay for epilepsy drug verdict
June 30, 2026
 · 
2 min read
 · 
Tristan Manalac
Set of crumpled lumps of different paper isolated on yellow background. Gritty dusty dotted effect, vector elements with jagged edges, old notebook sheets.
Regulatory
Amgen’s Tavneos troubles continue as NEJM retracts pivotal publication
June 30, 2026
 · 
2 min read
 · 
Tristan Manalac